Swatch shareholders reject bid by US investor to join board
Steven Wood, founder of U.S. firm GreenWood Investors, is pressing Swatch to focus more on its luxury brands such as Breguet and Blancpain in an attempt to turn around the fortunes of the Swiss company.
To be elected to the board he had to win over the Hayek family, which controls about 44% of Swatch voting rights.
The board had recommended Wood's bid be rejected before the firm's annual general meeting on Wednesday, and the company said 79.2% of shareholders voted against his election.
GreenWood holds about 0.5% of Swatch shares and Wood was seeking to represent so-called bearer shareholders, which have a majority of the share capital, but not of the voting rights.
After the vote, Wood said his bid had received strong support from investors, industry experts and Swatch employees, reinforcing his view that fresh perspectives on the board are essential to boost performance.
In a statement, Wood criticised how the vote was handled, and said he would consider requesting an extraordinary general meeting to ensure the election of a representative of the bearer shareholders is conducted in line with Swiss law.
Swatch said all motions were handled in accordance with legal requirements.
Proxy advisers Institutional Shareholder Services and Glass Lewis had recommended shareholders vote against the re-election of Swatch's supervisory board, questioning their independence.
Swatch is led by Chief Executive Nick Hayek, while his sister Nayla chairs the company that their father Nicolas helped create in the 1980s and built up into a global success story.
In late 2013, a year in which Swatch made net profits of over 1.6 billion Swiss francs ($1.9 billion), its shares were worth about 600 francs. Last year, profit dropped by 75% to 219 million francs. The stock now trades at less than 150 francs.
Swatch sales also slipped by nearly 15% last year, hit by sagging demand in China, which has also hurt luxury rivals like LVMH and Kering. Still, its Swiss peer and Cartier owner Richemont has retained its market appeal.
Richemont's watch sales ticked up slightly in 2024 and it has seen its shares rise almost a fifth so far this year. Swatch's stock is down by around 10% in 2025 and it is the most shorted on the Euro STOXX 600 index, according to LSEG data.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Euronews
42 minutes ago
- Euronews
EU-US trade deal leaves future of pharma tariffs uncertain
The current status of tariffs on pharmaceuticals between the EU and the US remains uncertain, despite the announcement on Sunday of a new transatlantic trade agreement. The situation is particularly sensitive given the mutual dependency in the sector: the US imports large volumes of critical pharmaceuticals from the EU, while EU-based pharmaceutical companies—especially in Ireland and Denmark—rely heavily on access to the American market. Although the new trade agreement will officially enter into force on 1 August, pharmaceuticals will not be subject to a 15% tariff which will be slapped on most goods imported from the European Union to the United States. This does not mean that there won't be tariffs at all on pharmaceuticals, as the US is still conducting an investigation into imported pharmaceuticals to assess whether they threaten US national security. For this reason, pharmaceuticals were technically excluded from yesterday's formal agreement, several EU sources confirm, as the US could not commit to any decision on tariff changes, which will only come after the conclusion of that process. However, if tariffs are introduced following the investigation, the EU expects the US—under President Trump—to honour the informal understanding reached during negotiations. This includes a cap of 15% on tariffs, which the EU considers "all-inclusive", meaning it should apply even to products still under investigation, such as pharmaceuticals and semiconductors. 'I believe that this commitment will be honoured and respected in this case as well,' said EU Trade Commissioner Maroš Šefčovič during a press briefing following the deal. So, what happens after 1 August? In the short term, nothing will change. Despite earlier reports suggesting the US would impose a 15% tariff on pharmaceuticals too in line with most EU goods, that is not expected to happen immediately. 'There will be no tariffs on pharmaceuticals this Friday,' clarified a senior EU official who participated in the negotiations with President Trump in Scotland. Most pharmaceutical products traded between the EU and the US currently benefit from a 0% tariff rate under the Most-Favoured Nation (MFN) framework. This is consistent with prior US-EU trade arrangements and World Trade Organization (WTO) commitments. As a result, EU pharmaceutical exports have faced no tariff barriers when entering the US market—a condition that remained unchanged even after Trump's so-called "Liberation Day", when he announced imposing blanket tariffs on goods. Uncertain outcome of the US investigation But tariffs on pharmaceuticals are expected to come at one point. The key uncertainty revolves around the ongoing Section 232 investigation being conducted by the Trump administration. This probe, authorised under the Trade Expansion Act of 1962, is intended to assess whether imports of pharmaceuticals (and other products as well such as semiconductors) threaten US national security. The investigation's conclusions could lead to unilateral actions by the US, including higher tariffs or import restrictions, independent of the broader trade deal struck yesterday. '[During the talks] President Trump wanted to make clear that they still have full freedom to conclude the 232 investigations and to choose any policy measures as a result,' said another EU negotiator. While EU officials cannot predict the outcome of the US investigation, they believe it is nearing completion. 'These are two investigations—pharmaceuticals and semiconductors—that are pretty close to conclusion,' an official noted. If the US does impose tariffs following the investigation, the EU expects these to be capped at 15% for both sectors, in line with the political understanding reached during the trade talks. EU's bet on pharma tariffs The EU's strategy is clear: even though Trump could not legally commit yesterday to tariffs on pharmaceuticals while the investigation is ongoing, the EU insisted on a 15% ceiling across all sectors, with no exclusions for pharmaceuticals. A senior EU official added that this understanding is backed by a broader political commitment, including planned investments by pharmaceutical companies in the US and pressure from the industry on both sides of the Atlantic to collaborate more closely. 'There is a clear understanding that investments, supply chain integration, and joint R&D efforts should all fall under the special 15% regime,' the official explained. Still, the EU acknowledges that this is not yet a legally binding commitment. 'Is this a legal commitment? No, not at this stage. That would have to come through an executive order once the US concludes its investigation,' the source continued. For now, both pharmaceutical and semiconductor products remain at zero-duty 0rates. No changes will occur on 1 August, but that could change once the US finalises its Section 232 investigation.
Euronews
3 hours ago
- Euronews
French MPs across the political spectrum slam US-EU trade agreement
France's Prime Minister François Bayrou said on Monday that the European Union had given in to US President Donald Trump's threats of increased tariffs, slamming the deal agreed to on Sunday as a "dark day." "It is a dark day when an alliance of free peoples, brought together to affirm their common values and to defend their common interests, resigns itself to submission," Bayrou wrote in a post on X. Under the agreed terms, finalised by European Commission President Ursula von der Leyen and Trump during a meeting in Scotland, the majority of EU exports bound for the American market will be subject to a 15% tariff. The tariff for US exports headed for the EU market was not immediately clear but the deal is preliminary and needs to be further fleshed out. "I think it's great we made a deal today instead of playing games," Trump said at the end of the meeting. "I think it's the biggest deal ever made." "It's a big deal. It's a huge deal," von der Leyen said. "It will bring stability, it will bring predictability. That's very important for businesses on both sides of the Atlantic." Von der Leyen noted the 15% tariff would be "across-the-board" and "all-inclusive", blocking the application of other duties. The trade agreement was also welcomed by Germany's Chancellor Friedrich Merz and the Italian Prime Minister, Giorgia Meloni. The EU's trade commissioner Maroš Šefčovič hailed it as a "breakthrough," preventing a potentially catastrophic trade war between the world's two biggest economies. Trade deal slammed in France But the deal has not been as well received by MPs in France from across the political spectrum. Benjamin Haddad, the Minister Delegate for European Affairs, welcomed the "temporary stability" the deal represents, but complained that it was "unbalanced." "Free trade has now been rejected by the United States, which has opted for economic coercion and complete disregard for WTO rules," he said in a post on X. "Let's be clear: the current state of affairs is unsatisfactory and unsustainable." President of the right-wing National Rally Jordan Bardella was more explicit in his condemnation, slamming it as an "agreement of shame." "Ursula von der Leyen accepted Europe's trade surrender, to the detriment of our exporters, farmers and manufacturers," he complained. His party colleague and leader of the National Rally in the National Assembly, Marine le Pen, was also critical, slamming the deal as a "political, economic and moral fiasco." Meanwhile, politicians on the left were equally critical. Founder of the France Unbowed (La France Insoumise) party, Jean-Luc Mélenchon, said the deal represented a blow to "liberalism" and complained that "everything has been ceded to Trump with the right to change the rules of the game established over 75 years of bilateral relations." And French MEP Raphaël Glucksmann said "this losing deal with Trump is the product of a despairing political and moral weakness." The end of the story? Before Trump's arrival disrupted transatlantic commerce, EU-made products were subject to an average tariff rate of 4.8% upon entering US territory. Sunday's deal presumably entails an additional 10% to reach the 15% mark. EU cars, which are today under a 27.5% tariff, will be brought under the 15% rate. A "zero-for-zero" scheme will apply to aircraft and related components, semiconductor equipment, critical raw materials and some chemical and agricultural products. "We will keep working to add more products to this list," von der Leyen said. Additionally, she explained, the bloc commits to spending over $250 billion per year on purchasing American liquefied natural gas (LNG), oil and nuclear fuels to replace Russian energy. The total pledge will amount to about $700 billion by the end of Trump's term. Asked about what concessions, if any, the US had made in the talks, the Commission chief replied with a general remark about shared prosperity. "The starting point was an imbalance, a surplus (of goods) on our side and a deficit on the US side. We wanted to rebalance the trade relation, and we wanted to do it in a way that trade goes on between the two of us across the Atlantic," she said. "I think it's going to be great for both parties," Trump said.
Fashion Network
4 hours ago
- Fashion Network
US and EU agree on 15% tariffs in new trade deal
The United States and the European Union (EU) have finalised a new trade agreement that introduces a 15% tariff on goods from all 27 EU member states, US President Donald Trump announced on Sunday. The announcement came after a meeting with European Commission President Ursula von der Leyen. Trump, who had earlier threatened to impose 30% tariffs on European products starting 1 August, confirmed that the agreement also includes $600 billion (£450 billion) in planned EU investments in the United States. Additionally, the European bloc committed to purchasing $750 billion (£562.5 billion) worth of American energy exports.
